Xi Jianxin,Chen Yuguo,Geng Xiaochen,et al.Perioperative efficacy study of recombinant humanized anti-CD25 monoclonal antibody combined with steroid minimization for immunoinduction in pediatric liver transplant recipients[J].Journal of Clinical Pediatric Surgery,2025,(03):207-214.[doi:10.3760/cma.j.cn101785-202412054-002]
Perioperative efficacy study of recombinant humanized anti-CD25 monoclonal antibody combined with steroid minimization for immunoinduction in pediatric liver transplant recipients
- Keywords:
- Liver Transplantation; Recombinant Humanized anti-CD25 Monoclonal Antibody; Acute Rejection; Glucocorticoids; Surgical Procedures; Operative; Child
- Abstract:
- Objective To observe the efficacy of recombinant anti-cluster of differentiation 25 (CD25) humanized monoclonal antibody plus steroid reduction immune induction regimen in preventing acute rejection (AR) in pediatric liver transplant (LT) recipients.Methods Retrospective analysis was conducted for 79 pediatric LT recipients between July 2015 and August 2024.Based upon perioperative immune induction regimens,they were assigned into two groups of full-dose steroid (n=60) and CD25 monoclonal antibody combined with half-dose steroid(n=19).The former group received full-dose steroid induction perioperatively,followed by tacrolimus plus steroids for postoperative immunosuppression.And the latter group received recombinant anti-CD25 humanized monoclonal antibody plus half-dose steroid induction perioperatively,followed by tacrolimus monotherapy for postoperative immunosuppression.The incidence rates of postoperative AR,infection,steroid-related complications and other primary outcomes were compared between two groups.Secondary outcomes,including intensive care unit (ICU) stay,graft survival,patient survival,length of hospitalization stay and hospitalization expenses were also compared.Results The incidence of AR (4/19 vs. 16/60),infection complications (12/19 vs. 40/60) and steroid-related complications (11/19 vs. 24/60) in CD25 monoclonal antibody combined with half-dose steroid group did not significantly differ from full-dose steroid group (P>0.05).Additionally,no significant inter-group differences existed in ICU stay,hospitalization expenses,graft survival rate (18/19 vs. 59/60) or patient survival rate (19/19 vs. 54/60) (P>0.05).However,length of hospitalization stay was significantly shorter in CD25 monoclonal antibody combined with half-dose steroid group than that in full-dose steroid group .Conclusions The recombinant anti-CD25 humanized monoclonal antibody plus steroid reduction immune induction regimen is both safe and effective,achieving similar immunosuppression with tapered steroid dosing.However,as compared with steroid group,it does not significantly lower the incidence of AR,infections or steroid-related complications.
References:
[1] 夏强,封明轩.中国儿童肝移植的现状与挑战[J].中华消化外科杂志,2024,23(1):49-54.DOI:10.3760/cma.j.cn115610-20240108-00013. Xia Q,Feng MX.Current status and existing challenges of pediatric liver transplantation in China[J].Chin J Dig Surg,2024,23(1):49-54.DOI:10.3760/cma.j.cn115610-20240108-00013.
[2] Ng VL,Fecteau A,Shepherd R,et al.Outcomes of 5-year survivors of pediatric liver transplantation:report on 461 children from a north American multicenter registry[J].Pediatrics,2008,122(6):e1128-e1135.DOI:10.1542/peds.2008-1363.
[3] Elisofon SA,Magee JC,Ng VL,et al.Society of pediatric liver transplantation:current registry status 2011-2018[J].Pediatr Transplant,2020,24(1):e13605.DOI:10.1111/petr.13605.
[4] Thangarajah D,O’Meara M,Dhawan A.Management of acute rejection in paediatric liver transplantation[J].Paediatr Drugs,2013,15(6):459-471.DOI:10.1007/s40272-013-0034-4.
[5] Jiang YZ,Zhao XY,Zhou GP,et al.Impact of immunosuppression level on liver allograft fibrosis after pediatric liver transplantation:a retrospective cohort study[J].Int J Surg,2023,109(11):3450-3458.DOI:10.1097/JS9.0000000000000631.
[6] 中华医学会器官移植学分会.中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J].中华移植杂志(电子版),2019,13(4):262-268.DOI:10.3877/cma.j.issn.1674-3903.2019.04.002. Branch of Organ Transplantation of Chinese Medical Association.Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J].Chin J Transplant (Electron Ed),2019,13(4):262-268.DOI:10.3877/cma.j.issn.1674-3903.2019.04.002.
[7] Zaydfudim V,Feurer ID,Landman MP,et al.Reduction in corticosteroids is associated with better Health-Related quality of life after liver transplantation[J].J Am CollSurg,2012,214(2):164-173.DOI:10.1016/j.jamcollsurg.2011.10.006.
[8] Gruttadauria S,di Francesco F,Pagano D,et al.Complications in immunosuppressive therapy of liver transplant recipients[J].J Surg Res,2011,168(1):e137-e142.DOI:10.1016/j.jss.2010.09.035.
[9] 段鑫,郑树森.肝移植术后无激素免疫抑制方案研究进展[J].中华移植杂志(电子版),2015,9(2):42-46.DOI:10.3877/cma.j.issn.1674-3903.2015.02.011. Duan X,Zheng SS.Advances in steroid-free immunosuppression after liver transplantation[J].Chin J Transplant (Electron Ed),2015,9(2):42-46.DOI:10.3877/cma.j.issn.1674-3903.2015.02.011.
[10] 董冲,孙超,陈静,等.巴利昔单抗联合减量糖皮质激素诱导免疫方案在儿童肝移植的临床应用[J].中华器官移植杂志,2021,42(3):136-140.DOI:10.3760/cma.j.cn421203-20201213-00421. Dong C,Sun C,Chen J,et al.Clinical observation of basiliximab plus single steroid induced immunotherapy during pediatric liver transplantation[J].Chin J Organ Transplant,2021,42(3):136-140.DOI:10.3760/cma.j.cn421203-20201213-00421.
[11] Rose JW.Anti-CD25 immunotherapy:regulating the regulators[J].SciTransl Med,2012,4(145):145fs25.DOI:10.1126/scitranslmed.3004440.
[12] Arabi F,Mansouri V,Ahmadbeigi N.Gene therapy clinical trials,where do we go?An overview[J].Biomed Pharmacother,2022,153:113324.DOI:10.1016/j.biopha.2022.113324.
[13] Goldschmidt I,Chichelnitskiy E,G?tz J,et al.Early steroids after pediatric liver transplantation protect against T-cell-mediated rejection:results from the ChilSFreestudy[J].Liver Transpl,2024,30(3):288-301.DOI:10.1097/LVT.0000000000000255.
[14] Segev DL,Sozio SM,Shin EJ,et al.Steroid avoidance in liver transplantation:meta-analysis and meta-regression of randomized trials[J].Liver Transpl,2008,14(4):512-525.DOI:10.1002/lt.21396.
[15] Becker T,Foltys D,Bilbao I,et al.Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation[J].Transplantation,2008,86(12):1689-1694.DOI:10.1097/TP.0b013e31818fff64.
[16] Otero A,Varo E,de Urbina JO,et al.A prospective randomized open study in liver transplant recipients:daclizumab,mycophenolate mofetil,and tacrolimus versus tacrolimus and steroids[J].Liver Transpl,2009,15(11):1542-1552.DOI:10.1002/lt.21854.
[17] Klintmalm GBG,Washburn WK,Rudich SM,et al.Corticosteroid-free immunosuppression with daclizumab in HCV+liver transplant recipients:1-year interim results of the HCV-3 study[J].Liver Transpl,2007,13(11):1521-1531.DOI:10.1002/lt.21182.
[18] Trune?ka P,Klempnauer J,Bechstein WO,et al.Renal function inde novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND study[J].Am J Transplant,2015,15(7):1843-1854.DOI:10.1111/ajt.13182.
[19] Crins ND,R?ver C,Goralczyk AD,et al.Interleukin-2 receptor antagonists for pediatric liver transplant recipients:a systematic review and meta-analysis of controlled studies[J].Pediatr Transplant,2014,18(8):839-850.DOI:10.1111/petr.12362.
[20] Zhang Y,JinW,CaiX.Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients:a systematic review and meta-analysis[J].Ann Med,2017,49(5):365-376.DOI:10.1080/07853890.2016.1257862.
[21] Wang XF,Li JD,Peng Y,et al.Interleukin-2 receptor antagonists in liver transplantation:a meta-analysis of randomized trials[J].Transplant Proc,2010,42(10):4567-4572.DOI:10.1016/j.transproceed.2010.09.169.
[22] Lupo L,Panzera P,Tandoi F,et al.Basiliximab versus steroids in double therapy immunosuppression in liver transplantation:a prospective randomized clinical trial[J].Transplantation,2008,86(7):925-931.DOI:10.1097/TP.0b013e318186b8a3.
[23] Lladó L,Xiol X,Figueras J,et al.Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications:results from a prospective multicenter randomized study[J].J Hepatol,2006,44(4):710-716.DOI:10.1016/j.jhep.2005.12.010.
[24] TeofiliL,Valentini CG,Aceto P,et al.High intraoperative blood product requirements in liver transplantation:risk factors and impact on the outcome[J].Eur Rev Med PharmacolSci,2022,26(1):64-75.DOI:10.26355/eurrev_202201_27749.
[25] Xue MJ,Lv CY,Chen XY,et al.Effect of interleukin-2 receptor antagonists on new-onset diabetes after liver transplantation:a retrospective cohort study[J].J Diabetes,2016,8(4):579-587.DOI:10.1111/1753-0407.12356.
[26] Hibi T,Shinoda M,Itano O,et al.Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis[J].Hepatol Res,2015,45(12):1178-1184.DOI:10.1111/hepr.12486.
[27] Calmus Y,Kamar N,Gugenheim J,et al.Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients[J].Transplantation,2010,89(12):1504-1510.DOI:10.1097/TP.0b013e3181db8cf0.
[28] Goralczyk AD,Hauke N,Bari N,et al.Interleukin 2 receptor antagonists for liver transplant recipients:a systematic review and meta-analysis of controlled studies[J].Hepatology,2011,54(2):541-554.DOI:10.1002/hep.24385.
[29] Cillo U,Bechstein WO,Berlakovich G,et al.Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression[J].Transplant Rev,2018,32(3):142-150.DOI:10.1016/j.trre.2018.04.001.
[30] Cantarovich M,Metrakos P,Giannetti N,et al.Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction[J].Transplantation,2002,73(7):1169-1172.DOI:10.1097/00007890-200204150-00030.
[31] Abrahamsson J,Sternby Eilard M,Rizell M,et al.Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation[J].Scand J Gastroenterol,2022,57(3):325-332.DOI:10.1080/00365521.2021.2010799.
[32] Moonka DK,Kim D,Kapke A,et al.The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation[J].Am J Transplant,2010,10(3):590-601.DOI:10.1111/j.1600-6143.2009.02880.x.
[33] Marubashi S,Dono K,Nagano H,et al.Steroid-free living donor liver transplantation in adults:impact on hepatitis C recurrence[J].Clin Transplant,2009,23(6):904-913.DOI:10.1111/j.1399-0012.2009.01022.x.
[34] Hanouneh IA,Zein NN,Lopez R,et al.IL-2 receptor antagonist (Basiliximab) is associated with rapid fibrosis progression in patients with recurrent hepatitis C after liver transplantation using serial biopsy specimens[J].Int J Organ Transplant Med,2010,1(1):7-14.
[35] Vimalesvaran S,Verma A,Dhawan A.Pediatric liver transplantation:selection criteria and post-transplant medical management[J].Indian J Pediatr,2024,91(4):383-390.DOI:10.1007/s12098-023-04963-5.
Memo
收稿日期:2024-12-19。
基金项目:国家自然科学基金(82241223,U20A20360)
通讯作者:吕国悦,Email:lvgy@jlu.edu.cn